Structured evidence table for Coenzyme Q10 Statin Myalgia Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Coenzyme Q10 Statin Myalgia Randomized Trial | Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Statin Myalgia Randomized Trial | Additionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Statin Myalgia Randomized Trial | Banach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence. | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Statin Myalgia Randomized Trial | Roth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Statin Myalgia Randomized Trial | Growing evidence implicates mitochondrial dysfunction, oxidative stress, and impaired muscle energy homeostasis as central drivers of statin-induced muscle injury, with important consequences for patient adherence and treatment durability. | 4 | Alabrahim OAA (2026) | Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity. |
| Coenzyme Q10 Statin Myalgia Randomized Trial | Mechanistically, these protective effects are associated with preservation of mitochondrial respiratory capacity, suppression of reactive oxygen species generation, and attenuation of pro-inflammatory signaling within muscle tissue, pathways directly implicated in muscle degeneration and impaired repair. | 4 | Alabrahim OAA (2026) | Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity. |
| Coenzyme Q10 Statin Myalgia Randomized Trial | Statins remain the cornerstone of atherosclerotic cardiovascular disease prevention; however, their long-term clinical utility is frequently limited by skeletal muscle toxicity, ranging from mild myalgia to severe myopathy. | 4 | Alabrahim OAA (2026) | Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity. |
Source documents